Genetic Link Between Gender Dysphoria and Sex Hormone Signaling.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 22 05 2018
accepted: 18 09 2018
pubmed: 25 9 2018
medline: 18 12 2019
entrez: 25 9 2018
Statut: ppublish

Résumé

There is a likely genetic component to gender dysphoria, but association study data have been equivocal. We explored the specific hypothesis that gender dysphoria in transgender women is associated with variants in sex hormone-signaling genes responsible for undermasculinization and/or feminization. Subject-control analysis included 380 transgender women and 344 control male subjects. Associations and interactions were investigated between functional variants in 12 sex hormone-signaling genes and gender dysphoria in transgender women. Patients were recruited from the Monash Gender Clinic, Monash Health, Melbourne, Australia, and the University of California, Los Angeles. Caucasian (non-Latino) transgender women were recruited who received a diagnosis of transsexualism [Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV) or gender dysphoria (DSM-V)] pre- or postoperatively. Most were receiving hormone treatment at the time of recruitment. Genomic DNA was genotyped for repeat length polymorphisms or single nucleotide polymorphisms. A significant association was identified between gender dysphoria and ERα, SRD5A2, and STS alleles, as well as ERα and SULT2A1 genotypes. Several allele combinations were also overrepresented in transgender women, most involving AR (namely, AR-ERβ, AR-PGR, AR-COMT, CYP17-SRD5A2). Overrepresented alleles and genotypes are proposed to undermasculinize/feminize on the basis of their reported effects in other disease contexts. Gender dysphoria may have an oligogenic component, with several genes involved in sex hormone-signaling contributing.

Identifiants

pubmed: 30247609
pii: 5104458
doi: 10.1210/jc.2018-01105
doi:

Substances chimiques

Gonadal Steroid Hormones 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

390-396

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Auteurs

Madeleine Foreman (M)

Hudson Institute of Research, Melbourne, Victoria, Australia.

Lauren Hare (L)

Hudson Institute of Research, Melbourne, Victoria, Australia.

Kate York (K)

Hudson Institute of Research, Melbourne, Victoria, Australia.

Kara Balakrishnan (K)

Hudson Institute of Research, Melbourne, Victoria, Australia.

Francisco J Sánchez (FJ)

University of Missouri, Columbia, Missouri.

Fintan Harte (F)

Monash Gender Clinic, Monash Health, Melbourne, Victoria, Australia.

Jaco Erasmus (J)

University of Missouri, Columbia, Missouri.

Eric Vilain (E)

Children's National Health System, Washington, DC.

Vincent R Harley (VR)

Hudson Institute of Research, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH